How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Remote Clinical Trials Market
- By Trial Phase: Phase I, Phase II, Phase III, Phase IV
- By Therapeutic Area: Oncology, Cardiology, Neurology, Endocrinology, Infectious Diseases
- By Technology Platform: Wearable Devices, Mobile Health Applications, Telemedicine Platforms, Electronic Patient-Reported Outcomes (ePRO), Remote Monitoring Devices
- By Service Provider: Clinical Research Organizations (CROs), Technology Vendors, Data Management Providers, Patient Recruitment Services
- By End User: Pharmaceutical Companies, Biotechnology Firms, Medical Device Companies, Academic Research Institutions
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Phase I leads By Trial Phase at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 298 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.180 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.188 →
Full report · locked preview
Everything inside the Remote Clinical Trials Market report
A complete, evidence-based study - 12 chapters and 125 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Trial Phase 4
Therapeutic Area 5
Technology Platform 5
Service Provider 4
End User 4
Companies profiled
IQVIA
Parexel International
PPD (Pharmaceutical Product Development)
ICON plc
Labcorp Drug Development (Covance)
Medable
Science 37
Signant Health
Clinipace
Castor EDC
Thread
ObvioHealth
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →IQVIA
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Parexel International
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →PPD (Pharmaceutical Product Development)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →ICON plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Labcorp Drug Development (Covance)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Medable
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Science 37
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Signant Health
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Clinipace
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Castor EDC
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Thread
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →ObvioHealth
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Clinical Ink
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →VirTrial
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Huma
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$7,506M by 2033 · 10.5% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Phase I50.2
- Phase II17.7
- Phase III12.3
- Phase IV19.8
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,113M → $2,331M · 9.7%
Europe$775.7M → $1,806M · 11.1%
Asia Pacific$708.3M → $1,763M · 12.1%
Latin America$438.5M → $1,043M · 11.4%
Middle East and Africa$337.3M → $802.0M · 11.4%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.472026
10.492027
10.492028
10.502029
10.522030
10.522031
10.542032
10.552033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- IQVIA21.1
- Parexel International21.0
- PPD (Pharmaceutical Product Development)8.5
- ICON plc11.1
- Labcorp Drug Development (Covance)4.8
- Medable5.5
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Trial Phase24.2%
Therapeutic Area11.4%
Technology Platform19.6%
Service Provider19.6%
End User25.3%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America30.1
- Europe23.3
- Asia Pacific22.8
- Latin America13.5
- Middle East and Africa10.4
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| IQVIA | 83 | 99 | 98 | 86 | 90 | 80 | 89 |
| Parexel International | 80 | 84 | 81 | 90 | 93 | 74 | 84 |
| PPD (Pharmaceutical Product Development) | 83 | 86 | 77 | 80 | 82 | 81 | 82 |
| ICON plc | 64 | 72 | 60 | 64 | 79 | 71 | 68 |
| Labcorp Drug Development (Covance) | 70 | 74 | 56 | 72 | 74 | 59 | 68 |
| Medable | 48 | 64 | 66 | 56 | 55 | 71 | 60 |
| Science 37 | 58 | 65 | 43 | 59 | 57 | 47 | 55 |
| Signant Health | 35 | 43 | 58 | 35 | 47 | 50 | 45 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- IQVIA
- Parexel International
- PPD (Pharmaceutical Product Development)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| IQVIA | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Parexel International | ✓ | ✓ | ◐ | ✓ | ◐ | ◐ |
| PPD (Pharmaceutical Product Development) | ◐ | ◐ | ✓ | ◐ | ✓ | ◐ |
| ICON plc | − | ◐ | ◐ | ◐ | ◐ | ✓ |
| Labcorp Drug Development (Covance) | ✓ | ◐ | − | ✓ | ✓ | − |
| Medable | − | − | − | ◐ | ◐ | ✓ |
| Science 37 | − | ◐ | − | − | − | − |
| Signant Health | − | − | ◐ | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1IQVIA89
2Parexel International84
3PPD (Pharmaceutical Product Development)82
4ICON plc68
5Labcorp Drug Development (Covance)68
6Medable60
7Science 3755
8Signant Health45
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
IQVIAParexel InternationalPPD (Pharmaceutical Product Development)
Challenger2
Strong scale, closing on the leaders.
ICON plcLabcorp Drug Development (Covance)
Contender1
Focused players with pockets of strength.
Medable
Niche2
Specialists in a single segment or region.
Science 37Signant Health
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Trial Phase in North America, then scale across Remote Clinical Trials Market — a $446M beachhead inside a $7.42B market.
Beachhead (SOM)$446Mobtainable near-term
Serviceable (SAM)$2.64Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Phase I
Best fit — highest urgency & budget in Trial Phase.
Economic buyer79 fit
Phase II
Strong fit — clear ROI and a fast path to value.
End user64 fit
Phase III
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Trial Phase in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Therapeutic Area & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Technology Platform
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel31%
Digital / self-serve18%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Trial Phase leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Remote Clinical Trials Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified22%
Evaluation13%
Closed-won7%
$9.6KCAC
$45KLTV
4.7:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Remote Clinical Trials Market is a resilient opportunity — $2.72B by 2033, compounding at 4.8%.
TAM · 2025$1.87Btoday
TAM · 2033$2.72Bforecast
CAGR4.8%2027–2033
Cumulative$20.4Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$2.72BTotal addressable market
SAM$1.11BServiceable available market
SOM$228MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →4.8% CAGR
Demand compounds through 2033, outpacing GDP across Trial Phase.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Trial Phase moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$2.72BLarge & growingTAM by 2033 at 4.8% CAGR
$1.11BServiceable nowreachable with today’s model
$228MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$2.12BBear3.1% CAGR
$2.72BBase4.8% CAGR
$3.49BBull6.4% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Therapeutic Area optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Remote Clinical Trials Market — a $9.82B market by 2033. Plan: grow share from 8.5% to 17.1%.
Market size · 2033$9.82Btotal addressable
Market CAGR8.1%2027–2033
Target share17.1%from 8.5% today
Revenue ambition$1.68Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.5% | 17.1% | On track |
| Revenue | $907M | $1.68B | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | At risk |
| Gross margin | 36.5% | 39.4% | Ahead |
| Customer retention | 85.0% | 95.7% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Trial Phase
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Therapeutic Area capability
A defensible second engine — invest in Therapeutic Area to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Trial Phase share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Therapeutic Area
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $222M capacity & capability investment
- Greenlight bolt-on M&A in Therapeutic Area
- Authorise North America expansion plan
- Fund R&D program for Trial Phase leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAhead
- Input-cost & supply riskAt risk
- Regulatory / policy changeAt risk
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Remote Clinical Trials Market conversation — a $5.50B market you can size, segment and defend in minutes.
Market size · 2033$5.50Btotal opportunity
Growth8.7%CAGR to 2033
Addressable buyers1,580+accounts in scope
Typical ROI6.8×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Trial Phase
Goal Grow share in Trial Phase
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.8×return on cost, year one
< 4 mopayback period
$81K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
IQVIAParexel InternationalPPD (Pharmaceutical Product Development)ICON plcLabcorp Drug Development (Covance)MedableScience 37Signant Health+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Remote Clinical Trials Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Remote Clinical Trials Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Remote Cardiac Monitoring Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportRemote Afterloading System Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportRemimazolam Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportRemifentanil Hydrochloride for Injection Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportRemicade (Infliximab) Monoclonal Antibody Market
Market size, share, segmentation and regional forecast.
$6.3B market · 2025 base year
View reportRemicade (Infliximab) and Biosimilar Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportRemdesivir (COVID-19) Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportRemdesivir API Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportRelugolix API Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportReloadable Linear Stapler Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportRelaxation and Meditation App Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportRelative Analgesia Machine Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.